PPARG and metabolic syndrome: Despite the fact that PPAR-γ activators are currently used as insulin sensitizers to combat type 2 diabetes and metabolic syndrome [25], PPAR-γ agonists in clinical use, represented by thiazolidinediones (TZD), have serious side effects such as weight gain, increased bone fracture, fluid retention, and heart failure [26].